Skip to content
value.today

Tempo Therapeutics, Inc.

Total raised
$20 M
2 rounds on record
Latest round
$16 M
Mar 2024
First round on record
May 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tempo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$16 MNo. 2$10 to $50 million

Tempo Therapeutics, Inc.: Raise no. 2, Mar 2024

Investors in this round

26 investors had bought by the notice of Mar 15, 2024: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $17 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Westbrook Weaver · Executive Officer, Director
  • Biren Mehta · Director
  • Donald Griffin · Director
  • Richard Hancock · Director
  • Robin Sitver · Director
  • Steven Richieri · Director
  • Steven Sands · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$12,034,004.38 new money; $1,800,164.38 conversion of notes; $2,493,496.14 conversion of SAFEs”

Signed by Westbrook Weaver, Chief Executive Officer. Newest notice filed Mar 15, 2024. Read the notice at the SEC.

equitySEC
May 2020$4 MNo. 1$2 to $10 million

Tempo Therapeutics, Inc.: Raise no. 1, May 2020

Investors in this round

39 investors had bought by the notice of Jun 2, 2020: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Steven Richieri · Executive Officer, Director
  • Westbrook Weaver · Executive Officer, Director, Promoter
  • Dino Di Carlo · Director
  • Donald Griffin · Director
  • Richard Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Westbrook Weaver, President. Newest notice filed Jun 2, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tempo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tempo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tempo Therapeutics, Inc.
NameRoleNamed in
Westbrook WeaverExecutive officerMar 2024
Steven RichieriExecutive officerJun 2020
Biren MehtaDirectorMar 2024
Donald GriffinDirectorMar 2024
Richard HancockDirectorMar 2024
Robin SitverDirectorMar 2024
Steven RichieriDirectorMar 2024
Steven SandsDirectorMar 2024
Westbrook WeaverDirectorMar 2024
Dino Di CarloDirectorJun 2020
Westbrook WeaverPromoterJun 2020